Literature DB >> 27755376

QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.

Konstantinos Balaskas1, Michael Karampelas, Mania Horani, Oana Hotu, Pearse Keane, Tariq Aslam.   

Abstract

PURPOSE: To assess whether best-corrected visual acuity and pigment epithelial detachment (PED) height, volume, and reflectivity in patients with wet age-related macular degeneration are influenced by baseline anatomical and functional parameters, including quantifiable metrics of PED morphology and choice of treatment.
METHODS: One hundred two consecutive, treatment-naive wet age-related macular degeneration patients with PED (>50 μm) treated with aflibercept (52) or ranibizumab (50) were retrospectively included. Pigment epithelial detachment height, horizontal and vertical dimensions, and volume were recorded at baseline, 3 months, and 1 year, respectively. Bespoke image analysis software provided a quantifiable measure of reflectivity.
RESULTS: Best-corrected visual acuity at 3 months was influenced by baseline best-corrected visual acuity (P = 0.006). Pigment epithelial detachment height was influenced by baseline height (P = 0.009), subretinal fluid (P = 0.008), central macular thickness (P = 0.006), and use of aflibercept (P = 0.003) at 3 months and by baseline height (P = 0.018), volume (P = 0.017), vertical dimension (P = 0.0004), and aflibercept (P = 0.015) at 1 year. Pigment epithelial detachment reflectivity increased from 43.59 to 55.86 (3 months) and 57.35 (1 year) (P < 0.001) and was influenced by its baseline values and, interestingly, use of aflibercept at 3 months (P = 0.013).
CONCLUSION: Quantifiable metrics of PED morphology improve with treatment, and PED content becomes hyperreflective, more so on aflibercept. Pigment epithelial detachments respond better in the context of more active disease. More hyporeflective PED content may predispose to better treatment response, especially with aflibercept.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27755376     DOI: 10.1097/IAE.0000000000001342

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  Impact of Delayed Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapy Due to the Coronavirus Disease Pandemic on the Prognosis of Patients with Neovascular Age-Related Macular Degeneration.

Authors:  Jae-Gon Kim; Yu Cheol Kim; Kyung Tae Kang
Journal:  J Clin Med       Date:  2022-04-21       Impact factor: 4.964

2.  The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Kai Xiong Cheong; Dilraj Singh Grewal; Kelvin Yi Chong Teo; Alfred Tau Liang Gan; Glenn Jay Jaffe; Gemmy Chui Ming Cheung
Journal:  Eye (Lond)       Date:  2020-02-11       Impact factor: 3.775

Review 3.  Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies.

Authors:  Yan Zhang; Catherine Chioreso; Marin L Schweizer; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-11-01       Impact factor: 4.799

4.  Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.

Authors:  Pallavi Tyagi; Zain Juma; Yong Keen Hor; Neil W Scott; Andreea Ionean; Cynthia Santiago
Journal:  BMC Ophthalmol       Date:  2018-06-22       Impact factor: 2.209

5.  Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV.

Authors:  Chinmayi Himanshuroy Vyas; Chui Ming Gemmy Cheung; Janice Marie N Jordan-Yu; Hitoshi Shimizu; Anna Cheng Sim Tan; Shaun Sebastian Sim; Beau James Fenner; Masahiro Akiba; Usha Chakravarthy; Kelvin Yi Chong Teo
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.